HIV初治患者两种酶抑制剂联合的疗效与安全性OACSTPCD

Objective To evaluate the efficacy and safety of albuvirtide therapy(ABT)combined with antiretroviral therapy(ART)in newly treated HIV patients.Methods A total of 163 patients with ART initiated in Tianjin Second People's Hospital from March 2021 to March 2022 were retrospectively analyzed and divided into compound monolithic integrase inhibitors(INSTIs)treatment group and the group of INSTIs combined with ABT.Virological inhibition,immune recovery,and safety were evaluated in the two groups of newly treated HIV patients treated with baseline age,sex,and CD4 count-matched combined monolithic integrase inhibitors(INSTIs)and ABT combined with combined INSTIs.Results A total of 57 patients with ABT plus INSTIs and 106 patients with INS-TIs were included.The rate of virological inhibition in the combined treatment group was higher than that in the monotherapy group at week 4 and 12,but there was no significant difference(61.1%vs.53.1%at week 4,P=0.618;87.8%vs.81.5%at 12 weeks,P=0.801),and virological inhibition rates were comparable between the two groups through 48 weeks of follow-up.CD4 count in the combination treatment group was higher than that in the monotherapy group at week 4(median 358 vs.194,P=0.042)and week 12(median 331 vs.249,P=0.044).CD4/CD8 ratios were also higher in the combined treatment group at week 4(median 0.28 vs.0.17,P=0.036)and week 12(median 0.33 vs.0.19,P=0.049)than in the monotherapy group,and CD4 counts were higher in both groups until 48 weeks of follow-up.There was no significant difference in CD4/CD8 ratio at each follow-up point.During 12 weeks of ABT treatment,only 1 patient developed mild atopic dermatitis,and no other adverse events occurred.Conclusions ABT combined with INSTIs is safe and well tolerated in patients with initial treatment of HIV,which can rapidly increase CD4 and decrease viral load within 12 weeks of treatment.